Shield Therapeutics notes UK launch of Feraccru® by Norgine

5 Dec 2018

Shield Therapeutics plc is pleased to note the announcement today by Norgine that they have launched Feraccru® in the UK. Feraccru® is a novel, effective and well tolerated treatment for Iron Deficiency in adults. In September 2018, Shield licensed Feraccru® to Norgine B.V. in most European territories. For full details please see the press release below:

Shield Therapeutics Press Release

To view the announcement released by Norgine, please click here.

 

 

Back to news